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This work
relates the development and validation of a simple reversed-phase
high-performance liquid chromatographic (HPLC) method for the
analysis of xanthone (XAN) and 3-methoxyxanthone (3-MeOXAN)
in poly(D,L-lactide-co-glycolide) (PLGA) nanocapsule formulations.
This method does not require any complex sample extraction
procedure. Chromatographic separation is made with a reversed-
phase C18 column, using methanol–water (90:10, v/v) as a mobile
phase at a flow rate of 1 mL/min. Identification is made by UV
detection at 237 nm. The isocratic system operates at ambient
temperature and requires 7 min of chromatographic time. The
developed method is statistically validated according to United
States Pharmacopoeia 25 and International Conference on
Harmonization guidelines for its specificity, linearity, accuracy,
and precision. The assay method proposed in this study is specific
for XAN and 3-MeOXAN in the presence of nanocapsule excipients.
Diode-array analyses confirm the homogeneity of XAN and
3-MeOXAN peaks in stressed conditions. Standard curves are linear
(r > 0.999) over the concentration range of 0.4–2.5 and 1.0–5.8
µg/mL for XAN and 3-MeOXAN, respectively. Recovery from
nanocapsules ranges from 99.6% to 102.8% for XAN and 98.8%
to 102.4% for 3-MeOXAN. Repeatability (intra-assay precision)
is acceptable with relative standard deviation values of 1.2% for
XAN and 0.3% for 3-MeOXAN.
Introduction
Xanthones represent a large group of heterocyclic compounds
including natural, semisynthetic, and totally synthetic structures
(1). Chemically, xanthonic nucleus corresponds to dibenzo-γ-
pyrone. Xanthone (XAN) molecules, having a variety of sub-
stituents on the different carbons of the nucleus, constitute a
group of compounds with a broad spectrum of biological activi-
ties. Among others, antitumoral (2,3), antibacterial (4), anti-
inflammatory (5), hepatoprotective (6), antimalarial (7),
immunomodulatory (8,9), as well as inhibitory activities of
angiotensin converting enzyme (10) and monoamine oxidase
(MAO) (11,12) have been described. Xanthone itself was described
as a good MAO-A inhibitor (13).
Poor aqueous solubility of XAN andmany of its derivatives such
as 3-methoxyxanthone (3-MeOXAN) (Figure 1) is a major
obstacle for the assessment of the pharmacological activity of
these compounds and their use in the therapy. In general, besides
the difficulties of administration of drug substances, water in-
solubility is often associated with poor bioavaliability (14).
One approach to overcome the difficulty of administration of
poorly water-soluble compounds is by their incorporation in car-
rier systems such as polymeric microparticles and nanoparticles.
The efficiency of this approach was successfully proven for dif-
ferent drugs (15–17). Nanoparticles are solid submicronic drug
carriers of a polymeric nature in the nanometer size (18).
According to the process used for preparation of nanoparticles,
nanospheres or nanocapsules can be obtained. Nanocapsules are
vesicular systems in which the drug is confined to a cavity sur-
rounded by a polymeric membrane; nanospheres are matrix sys-
tems inwhich the drug is dispersed throughout the particles (19).
Besides the improvement of delivery of water-insoluble drugs,
nanoparticles have afforded several advantages for different drugs
such as reducing drug-associated adverse effects (19), protecting
the compound from inactivation before reaching its site of action
(20), and increasing the intracellular penetration (21).
By incorporating XAN or its derivatives (such as 3-MeOXAN) in
nanoparticles, these poorly water-soluble compounds may be
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Figure 1. Chemical structure of xanthones: XAN (R = H) and 3-MeOXAN
(R = OCH3).
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administered as nanoparticle aqueous dispersions at concentra-
tions higher than their maximum hydrosolubility. Moreover, the
incorporation of these compounds in nanoparticles may also
allow different ways of administration and, simultaneously, may
afford their in vivo protection and targeting.
In our laboratory we routinely carry out in vitro studies with
poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing
either xanthone or xanthone derivatives in order to test the use-
fulness of these colloidal systems as potential carriers for this
group of compounds. For this purpose, the estimation of nanopar-
ticle content is an essential tool for guarantying the reliability of
the results. The aim of this work was to develop and validate a spe-
cific, sensitive, and simple high-performance liquid chromatog-
raphy (HPLC) method for the quantitative analysis of XAN and
3-MeOXAN, which were entrapped in PLGA nanocapsules for the
first time. PLGA has been selected because polyesters including
poly(lactic acid), poly(glycolic acid), and their copolymers such as
PLGA have emerged as themost widely studied class of biodegrad-
able polymers for pharmaceutical use because of their biocompat-
ibility and biodegradability (22). The procedures and parameters
used for validation of the analytical method were those described
in the International Conference on Harmonization (ICH) guide-
lines (23,24), which are similar to the ones established by the
United States Pharmacopoeia (USP) (25).
Experimental
Reagents and chemicals
XAN, PLGA (50:50, MW 50,000–75,000), Pluronic F-68, and
soybean lecithin (40%purity by thin-layer chromatography) were
purchased from Sigma (Madrid, Spain). 3-MeOXAN was synthe-
sized in our laboratory by alkaline cyclization of 2-hydroxy-2',4-
dimethoxybenzophenone (26).Myritol 318was kindly supplied by
Henkel (Lisbon, Portugal). HPLC-grade methanol and acetoni-
trile were obtained fromMerck (Whitehouse Station, NJ). HPLC-
grade water was obtained by a MilliQ system (Millipore, Billerica,
MA). Other chemicals were of analytical grade.
Nanocapsule preparation and characterization
XAN and 3-MeOXAN nanocapsules of PLGA were prepared
according to a modification of the interfacial polymer deposition
method described by Fessi et al. (27). Approximately 50 mg of
polymer and 100 mg of soybean lecithin were briefly dissolved in
10mL of acetone. XAN (7.2mg) or 3-MeOXAN (16.8mg) was dis-
solved in 0.6 mL of Myritol 318, and the obtained solution was
added to the acetonic solution. The final solution was poured into
20 mL of an aqueous solution of pluronic F-68 (0.5%, w/v) under
moderate stirring, leading to the formation of nanocapsules.
Acetone was then removed under vacuum, and the colloidal dis-
persion of nanocapsules was concentrated to 5mL by evaporation
under reduced pressure. Nonencapsulated xanthones (XAN or 3-
MeOXAN) were separated by ultrafiltration/cetrifugation using
centrifugal filter devices Centricon YM-50 (Millipore).
Empty nanocapsules were prepared according to the same pro-
cedure, but omitting xanthones in the organic phase.
Themean size and polydispersity index of aqueous nanocapsule
dispersions were determined by laser light scattering (Zetasizer
5000, Malvern Instruments, Worcestershire, U.K.) generating a
volume-average distribution for analyzed data.
Instrumental and chromatographic conditions
HPLC analysis was performed with a Jasco liquid chromato-
graph (Easton, MD) equipped with a Jasco 880-PU pump and a
Jasco 875-UV spectrophotometric detector. The separation was
carried out on a 250- × 4.6-mm i.d. Nucleosil C18 column (5 µm)
(Macherey-Nagel, Düren, Germany). Liquid chromatography
analysis was performed by isocratic elution. The mobile phase
composition was methanol–water (90:10, v/v), and the flow rate
was set at 1.0 mL/min. The injected volume was 20 µL, and the
detection wavelength was set at 237 nm. CWS 1.7 software
(DataApex, Prague, Czech Republic) managed chromatographic
data.
Analysis of samples of XAN and 3-MeOXAN subjected to
thermal, acid, and alkaline stress conditions was also performed
by HPLC using a different system equipped with a diode-array
detector. A Spectra System liquid chromatograph equipped with
a Series II digital pump (Science Marketing International,
Gloucester, U.K.) with diode-array UV6000LP detector
(ThermoFinnigan, San Jose, CA) was used. Samples were chro-
matographed using the same procedure described previously,
including the used column, injected volume, and detection wave-
length. Chromquest forWindows NT software (ThermoFinnigan)
managed chromatographic data.
Preparation of sample solutions for determination of XAN and
3-MeOXAN in nanocapsules
Sample solutions were obtained by dissolving an aliquot of XAN
or 3-MeOXAN nanocapsule dispersion in acetonitrile (corre-
sponding to a dilution of 1/1000) and subjected to HPLC analysis.
Considering 100% of entrapment of xanthones in nanocapsules,
the obtained sample solutions had a maximum theoretical con-
centration (MTC) of 1.44 and 3.36 µg/mL of XAN and 3-MeOXAN,
respectively. All analyses were performed in triplicate, and the
mean results are reported.
Preparation of XAN and 3-MeOXAN standard solutions
Stock standard solutions of XAN and 3-MeOXAN (50 µg/mL)
were prepared in acetonitrile. XAN and 3-MeOXAN standard solu-
tions were obtained by dilution of the respective freshly prepared
stock standard solution with acetonitrile to give six different con-
centrations over the range of interest (0.4–2.5 µg/mL for XAN and
1.0–5.8 µg/mL for 3-MeOXAN).
Results and Discussion
Method development
The methanol–water ratio in mobile phase and flow rate were
selected in order to find the best conditions for the determination
and quantitation of XAN and 3-MeOXAN in nanocapsule formula-
tions. Amobile phase of methanol–water (90:10, v/v) was selected
to achieve good separation and sensitivity. A flow rate of 1.0
mL/min gave an optimal signal-to-noise ratio and a reasonable
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separation time. Retention times were 5.3 min for XAN and 5.8
min for 3-MeOXAN. The total time required for analysis was 7
min. The maximum absorption of both compounds in the exper-
imental conditions was found to be 237 nm. Therefore, this wave-
length was chosen for the analysis.
For preparation of sample solution of nanocapsules containing
XAN or 3-MeOXAN, different solvents (acetonitrile and
dichloromethane) were evaluated in order to achieve a complete
dissolution of nanocapsule aqueous dispersions. Acetonitrile was
found to afford a complete dissolution upon a 1000-fold dilution
of aliquots of XAN or 3-MeOXAN nanocapsule dispersions.
Validation study
Specificity
According to ICH guidelines, the specificity of an analytical
method is the ability to assess unequivocally the analyte in the
presence of components that may be expected to be present such
as impurities, degradation products, excipients, etc. (23,24).
Figure 2. Representative chromatograms obtained following the injection of: (1A) XAN, 1.4 µg/mL; (2A) 3-MeOXAN, 1.0 µg/mL; (1B) XAN and (2B) 3-MeOXAN stan-
dard solutions spiked with empty nanocapsules; (1C) XAN and (2C) 3-MeOXAN subjected to thermal degradation, 120°C for 2 h; (1D) XAN and (2D) 3-MeOXAN sub-
jected to acid degradation, HCl 1N for 24 h; and (1E) XAN and (2E) 3-MeOXAN subjected to basic degradation, NaOH 1N for 24 h.
40
30
30
25
20
15
10
5
0
200
175
150
125
100
75
50
25
0
30
25
20
15
10
5
0
0 1 2 3 4 5 6 7
0 1 2 3 4 5 6 7
20
10
0
30
20
10
0
0
100
80
60
40
20
0
1
3
3 4 5 6
3 4 5 6
5
4
3
2
1
0
8
6
4
2
0
7
6
5
4
3
2
1
0
5
4
3
2
1
0
4 5 6 3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
2 3 4 5 6 7
0 1 2 3 4 5
5.2
9
5.3
1
5.4
2
2.7
3
2.8
5
2.7
6
5.3
7
5.4
1
2.7
7
3.3
5
5.6
4
5.5
9
5.8
4
2.8
1
2.7
8
5.8
1
5.8
1
2.7
7
6
Journal of Chromatographic Science, Vol. 41, August 2003
374
In the present study, the specificity of the analyticalmethodwas
determined either in samples subjected to stress conditions or in
samples containing nanocapsule excipients (i.e., spiked with
empty nanocapsules). Samples of both xanthones were subjected
to thermal, acidic, and alkaline stress conditions. For the evalua-
tion of thermal degradation, portions of XAN and 3-MeOXAN
were placed in an oven at 120ºC for 2 h. Afterwards, samples were
dissolved in methanol and subjected to HPLC analysis. For the
evaluation of the degradation of xanthones in acidic and alkaline
conditions, a known amount (1 mg) of XAN or 3-MeOXAN was
mixed with 25mL of HCl 1N or NaOH 1N, and the obtained prod-
ucts were stored at room temperature for 24 h. After filtration,
solutions were appropriately neutralized with HCl 1N or NaOH
1N and diluted with methanol for HPLC analysis. Controls and
blank preparations were also prepared and assayed.
Figure 2 shows representative chromatograms of XAN (1A) and
3-MeOXAN (2A) standard solutions. Retention times were 5.3
min for XAN and 5.8 min for 3-MeOXAN. No peaks interfering
with XAN or 3-MeOXAN could be detected. A peak with a reten-
tion time between 2.8 and 3.0 min, because of the solvent front,
was observed. Chromatograms corresponding to xanthone sam-
ples subjected to thermal, acidic, and alkaline stress conditions
are also shown in Figure 2 (1C–E and 2C–E). No interfering peaks
with retention times similar to those of XAN or 3-MeOXAN were
observed from any of the stressed samples. Comparison of diode-
array spectra, which were obtained at the leading edge, apex, and
trailing edge of the XAN and 3-MeOXAN peaks, were identical.
This peak purity check, made possible by diode-array technology,
is a good indication for the absence of interfering peaks.
In order to evaluate the specificity of the analytical method con-
cerning the presence of nanocapsule excipients (i.e., the potential
interference of the excipients), a comparison of the test results
from the analysis of XANand3-MeOXANstandard solutions spiked
with empty nanocapsules with those obtained from the analysis of
XAN and 3-MeOXAN standard solutions alone was
carried out. Obtained chromatograms (Figure 2,
1B and 2B) show the absence of any peak in the
region where xanthones elute, which indicates that
the method is specific concerning to nanocapsule
excipients.
Linearity and range
According to ICH guidelines, the linearity of an
analytical method is its ability (within a given
range) to obtain test results that are directly pro-
portional to the concentration of analyte in the
sample (23,24).
Linear regression analysis was carried out by
plotting average peak area (y) versus analyte con-
centration (x) in the concentration range of
0.4–2.5 µg/mL for XAN and 1.0–5.8 µg/mL for 3-
MeOXAN. Calibration curves were constructed at
six concentration levels using the linear-squares
regression procedure. The overall procedure was
repeated three times on different days. The peak
Table II. Results of Accuracy Determinations
XAN 3-MeOXAN
Theoretical Experimental Theoretical Experimental
concentration concentration concentration concentration
(µg/mL) %MTC (µg/mL) Recovery (%) (µg/mL) %MTC (µg/mL) Recovery (%)
0.4 28 0.410 102.58 1.0 30 1.024 102.38
0.4 28 0.411 102.75 1.0 30 1.017 101.66
0.4 28 0.401 100.25 1.0 30 1.011 101.14
1.0 69 1.004 100.40 2.4 71 2.371 98.77
1.0 69 1.001 100.09 2.4 71 2.416 100.69
1.0 69 1.000 100.01 2.4 71 2.428 101.16
1.4 97 1.395 99.64 3.4 101 3.398 99.95
1.4 97 1.412 100.86 3.4 101 3.423 100.67
1.4 97 1.394 99.61 3.4 101 3.454 101.58
Mean recovery (%) 100.69 Mean recovery (%) 100.89
RSD (%) 1.18 RSD (%) 1.04
Table I. Summary of Standard Curve Results
XAN 3-MeOXAN
Average peak Average peak
Concentration area response Concentration area response
(µg/mL) (mV) RSD (%) (µg/mL) (mV) RSD (%)
0.4 126.50 1.74 1.0 260.55 2.67
0.6 187.75 1.34 1.7 442.67 1.30
0.7 217.55 2.00 2.4 628.46 2.56
1.0 312.27 3.74 3.4 905.49 1.77
1.4 426.89 3.74 4.0 1054.74 2.39
2.5 777.79 1.37 5.8 1554.73 2.69
Y-intercept 0.9386 ± 3.925 –14.66 ± 10.30*
Slope 309.6 ± 3.01 269.6 ± 3.00*
Correlation coefficient (r) 0.999246 0.999014
Coefficient of 0.998492 0.998029
determination (R2)
* Confidence limits (P = 0.05).
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area values obtained for three replicate analyses were averaged at
each concentration.
Obtained calibration curves showed to be linear over the con-
centration ranges examined for XAN and 3-MeOXAN, giving cor-
relation coefficients (r) greater than 0.999 and coefficients of
determination (R2) greater than 0.9980 (i.e., over a 99.8% rela-
tionship between x and y) (Table I).
Accuracy
According to ICH guidelines, the accuracy of an analytical
method expresses the closeness of agreement between the value
that is accepted either as a conventional true value or an accepted
reference value and the value found (23,24). Accuracy is often cal-
culated as percent recovery by the assay of known, added amounts
of analyte to the sample. Accuracy should be assessed using a
minimum of nine determinations over a minimum of three con-
centration levels.
Accuracy was determined by spiking known amounts of XAN or
3-MeOXAN to aqueous dispersions of empty nanocapsules in
order to obtain XAN concentrations of 0.4, 1.0, and 1.4 µg/mL
(corresponding approximately to 28%, 69%, and 97% of MTC)
and 3-MeOXAN concentrations of 1.0, 2.4, and 3.4 µg/mL (corre-
sponding approximately to 30%, 71%, and 101% of MTC). Table
II summarizes the accuracy results, expressed as percent recovery
and relative standard deviation (RSD). Recovery data were within
the range of 99.61–102.75% (RSD = 1.18%) and 98.77–102.38%
(RSD = 1.04%) for XAN and 3-MeOXAN, respectively. Overall
mean recovery values were 100.69% (n= 9) for XAN and 100.89%
(n = 9) for 3-MeOXAN. Because the mean recovery results were
within an acceptable ± 3% range, according to Segall et al., the
method was deemed to be accurate (28).
Precision
According to ICH guidelines, the precision of an analytical
method expresses the closeness of agreement between a series of
measurements obtained from multiple sampling of the same
homogeneous sample under the prescribed conditions (23,24).
Precision may be measured as repeatability (also termed “intra-
assay precision”). Repeatability expresses the precision under the
same operating conditions over a short interval of time. ICH
guidelines recommend that repeatability should be assessed
using a minimum of nine determinations covering the specified
range (i.e., three concentrations and three replicates for each
concentration) or a minimum of six determinations of 100% of
the test concentration.
In the present study, precision of the analytical method was
determined by the analysis, on the same day, of six independently
prepared standard solutions (1.4 µg/mL for XAN and 3.4 µg/mL
for 3-MeOXAN), corresponding to approximately 100% of MTC.
Obtained RSD values (1.09% for XAN and 1.38% for 3-MeOXAN)
indicate that the proposed HPLC method shows acceptable
repeatability (Table III). These results are in agreement to the cri-
teria proposed by Green for the precision of an analytical method,
for which the RSD should be lower than 2% (29).
Application of the developed method to the quantitative
determination of XAN and of 3-MeOXAN in nanocapsules
The present validated method was used to determine either
XAN or 3-MeOXAN encapsulated in different nanocapsule
batches. Table IV shows encapsulation parameters and particle
size of prepared PLGA nanocapsule formulations. High encapsu-
lation efficiency values of xanthones in PLGA nanocapsules
(84.1% for XAN and 81.2% for 3-MeOXAN) were obtained. The
mean particle size of XAN and 3-MeOXAN nanocapsules was 231
nm and 245 nm, respectively.
Conclusion
A simple isocratic reversed-phase HPLCmethod was developed
for the determination of XAN and 3-MeOXAN in PLGA nanocap-
sule formulations. The method was validated according to ICH
guidelines and USP 25 for its specificity, linearity, accuracy, and
precision. Results of validation showed that the proposedmethod
is specific, linear, accurate, and precise either for XAN or 3-
MeOXAN, within the established ranges.
XAN and 3-MeOXAN nanocapsule formulations were prepared
for the first time. No degradation of the compounds was found
Table IV. Encapsulation Parameters and Mean Particle
Size of PLGA Nanocapsule Formulations Containing XAN
or 3-MeOXAN*
Theoretical
concentration Encapsulation Polidispersity
(mg/mL)† efficiency (%)‡ Diameter (nm) index§
XAN nanocapsules
1.4 84.1 ± 4.9 230.6 ± 11.2 0.483
3-MeOXAN nanocapsules
3.4 81.2 ± 3.0 244.5 ± 29.8 0.431
* Values express the mean results ± standard deviation values of different batches
(n = 4 for XAN nanocapsules and n = 3 for 3-MeOXAN nanocapsules.
† Amount of compound (XAN or 3-MeOXAN) used to prepare nanocapsule/volume of
nanocapsule dispersion.
‡ (Actual concentration/theorectical concentration) × 100.
§ Varies from 0.0 corresponding to a perfect homogeneous dispersion to 1.0 corre-
sponding to a complete heterogeneous dispersion.
Table III. Results of Precision Determinations
XAN 3-MeOXAN
Sample n° Peak area Sample n° Peak area
(1.4 µg/mL)* response (mV) (3.4 µg/mL)* response (mV)
1 449.9145 1 884.4430
2 451.3571 2 889.3809
3 452.3661 3 904.2599
4 440.0680 4 895.9607
5 453.6449 5 909.3888
6 451.3571 6 876.6475
Average peak 449.7846 Average peak 893.3468
area (mV) area (mV)
RSD (%) 1.09 RSD (%) 1.38
* Corresponding to approximately 100% of MTC in nanocapsule sample solution.
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upon nanocapsule preparation by the adopted interfacial polymer
deposition method, and high encapsulation efficiencies were
obtained. Results clearly demonstrate the suitability of this
method for incorporating both poorly water-soluble compounds
in PLGA nanocapsules. In vitro studies are being undertaken in
different cell lines in order to test the potential of these colloidal
delivery systems for xanthone and its derivatives.
The presently developed and validated HPLC method was suc-
cessfully used to determine either XAN or 3-MeOXAN content in
nanocapsule formulations, affording a very important tool for the
evaluation of the finished products. The method could also be
useful for the quantitation of different xanthone derivatives
encapsulated in nanocapsules. However, further validation
studies should be performed for each compound.
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